Table 3.
Clinical characteristics of 29 patients with primary biliary cholangitis in a longitudinal study of 18 years.
| Baseline characteristic | Overall (n = 29) | Survivor (n = 21) | Death (n = 8) | Survivor vs. death | |||
|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | P value | |
| Age (years) | 55 | (45–61) | 55 | (46–61) | 56 | (44–63) | 0.83 |
| Female/Male | 27/2 | 19/2 | 8/0 | 0.37 | |||
| Laboratory data | |||||||
| alkaline phosphatase (U/L) | 413 | (314–635) | 405 | (314–635) | 500 | (310–644) | 0.78 |
| gamma-glutamyl transpeptidase (U/L) | 97 | (53–210) | 100 | (72–267) | 46 | (28–170) | 0.10 |
| alanine aminotransferase (U/L) | 35 | (30–52) | 36 | (30–52) | 33 | (29–55) | 0.64 |
| aspartate aminotransferase (U/L) | 42 | (32–54) | 41 | (35–54) | 48 | (31–58) | 0.68 |
| total bilirubin (mg/dL) | 0.81 | (0.60–0.81) | 0.87 | (0.60–0.94) | 0.75 | (0.59–1.06) | 0.87 |
| albumin (g/dL) | 4.0 | (3.8–4.3) | 4.1 | (3.9–4.3) | 3.7 | (3.5–4.4) | 0.23 |
| platelet count (x104/µL) | 19.1 | (16.3–22.6) | 18.8 | (16.4–22.6) | 19.4 | (10.1–22.7) | 0.74 |
| immunoglobulin M (mg/dL) | 312 | (176–614) | 355 | (234–614) | 180 | (120–595) | 0.20 |
| immunoglobulin G (mg/dL) | 1,576 | (1,306–1,878) | 1,576 | (1,306–1,807) | 1,816 | (1,209–2,325) | 0.45 |
| AMA-M2 positive (%) | 24 (83%) | 18 (86%) | 6 (75%) | 0.49 | |||
| anti-nuclear antibody positive (%) (x80) | 23 (79%) | 16 (71%) | 8 (100%) | 0.09 | |||
| Fibrosis markers | |||||||
| ATX (mg/L) | 0.93 | (0.86–1.07) | 0.91 | (0.79–1.29) | 1.11 | (1.02–1.17) | 0.06 |
| fibrosis index based on four factors index | 1.91 | (1.73–2.48) | 1.86 | (1.73–2.45) | 2.41 | (1.58–5.96) | 0.29 |
| aspartate aminotransferase-to-platelet ratio index | 0.77 | (0.61–1.03) | 0.77 | (0.68–1.00) | 0.86 | (0.50–2.98) | 0.74 |
| Initial treatment | |||||||
| ursodeoxycholic acid 300/600/900 | 6/22/1 | 5/15/1 | 1/7/0 | 0.63 | |||
Data are expressed as the number (%) or median (first-third quartiles).
Abbreviations: IQR, interquartile range; AMA-M2, anti-mitochondrial antibody specific for the pyruvate dehydrogenase complex-E2 component; ATX, autotaxin.